[P-2] Poster Talk2

[P2-3] Intranasal COVID-19 vaccine with ODN2006 induces cross-protective IgA antibodies with reducing the risk of lung eosinophilic immunopathology

*Takuya Hemmi^1,2, Akira Ainai^1,2, Takao Hashiguchi^3,4, Minoru Tobiume¹, Takayuki Kanno¹, Naoko Iwata-Yoshikawa¹, Shun Iida¹, Sho Miyamoto¹, Akira Ueno^1,5, Kaori Sano¹, Shinji Saito¹, Nozomi Shiwa-Sudo¹, Noriyo Nagata¹, Koji Tamura², Ryouke Suzuki^2,6, Hideki Hasegawa⁷, Tadaki Suzuki¹ (1. Department of Pathology, National Institute of Infectious Diseases, 2. Department of Biological Science and Technology, Tokyo University of Science, 3. Laboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, 4. Department of Virology, Faculty of Medicine, Kyushu University, 5. Department of Life Science and Medical Bioscience, Waseda University, 6. Department of Virology II, National Institute of Infectious Diseases, 7. Research Center for Influenza and Respiratory Virus, National Institute of Infectious Diseases)